Four EGFR TKIs are approved by the US Food and Drug Administration (FDA) for use in NSCLC patients (erlotinib [Tarceva], gefitinib [Iressa], afatinib [Gilotrif], and osimertinib [Tagrisso]), and several others are in development. This evidence concerns the gene EGFR and non-small cell lung carcinoma.